Supernus Pharmaceuticals, Inc. Free Cash Flow 2010–2025
Supernus Pharmaceuticals, Inc. reported $45.99M of free cash flow for fiscal 2025. That was 73.1% lower than fiscal 2024. Compared with fiscal 2020, the change was -65.9%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $45.99M | -73.1% |
| FY 2024 | $171.23M | +54.9% |
| FY 2023 | $110.53M | -5.1% |
| FY 2022 | $116.41M | -8.4% |
| FY 2021 | $127.13M | -5.8% |
| FY 2020 | $134.95M | -3.9% |
| FY 2019 | $140.39M | +9.6% |
| FY 2018 | $128.14M | +13.8% |
| FY 2017 | $112.61M | +72.7% |
| FY 2016 | $65.21M | +101.1% |
| FY 2015 | $32.42M | +229.2% |
| FY 2014 | $-25.09M | +57.9% |
| FY 2013 | $-59.59M | -24.3% |
| FY 2012 | $-47.95M | -30.1% |
| FY 2011 | $-36.87M | -12.3% |
| FY 2010 | $-32.84M | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SUPN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Supernus Pharmaceuticals, Inc. reported $45.99M of free cash flow for fiscal 2025. That was 73.1% lower than fiscal 2024. Compared with fiscal 2020, the change was -65.9%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s free cash flow?
Supernus Pharmaceuticals, Inc. (SUPN) reported free cash flow of $45.99M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.